research Efficacy of Barictinib As Compared to Conventional Therapy as a Treatment for Alopecia Areata
Baricitinib is effective for Alopecia Areata but requires careful patient history evaluation.
Search
for
Sort by
Research
780-810 / 1000+ results research Trichoscopy of Steroid-Induced Atrophy
Use lower concentrations of triamcinolone acetonide to reduce steroid-induced scalp atrophy.
research Comparative analysis of temperature‐controlled cryotherapy versus intralesional triamcinolone acetonide injection for alopecia areata: An intrasubject split‐lesion pilot study
Cryotherapy with precise temperature control is a promising treatment for alopecia areata.
research Alopecia in Patients with Autoimmune Hepatitis Treated by Tacrolimus Therapy
Tacrolimus treatment for autoimmune hepatitis can cause hair loss.
research P123 : Oral Janus kinase inhibitors for the treatment of alopecia areata: a systematic review and metaanalysis
Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
research Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
research Efficacy and safety of dual-targeted therapy for refractory inflammatory bowel disease: a retrospective case series from three tertiary general hospitals in China
Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.
research Practices, Efficacy, and Reported Side Effects Associated with Isotretinoin Treatment in Palestine
Isotretinoin treatment in Palestine shows poor adherence to guidelines, with common side effects and a need for better prescribing practices and patient education.
research Role of janus kinase inhibitors in the treatment of alopecia areata
Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
research Upadacitinib for Alopecia: Current Evidence and Clinical Insights
Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.
research JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.
research Efficacy of Janus Kinase Inhibitors in Alopecia in Jordanian Patients: A Retrospective Cohort Study
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
research Enhancement of Intermittent Androgen Ablation Therapy by Finasteride Administration in Animal Models
research Enhancement of Intermittent Androgen Ablation Therapy by Finasteride Administration in Animal Models
research Enhancement of Intermittent Androgen Ablation Therapy by Finasteride Administration in Animal Models
research Treatment of moderate-to-severe alopecia areata in patients over the age of 65 with baricitinib
Baricitinib helps treat severe hair loss in people over 65.
research Strong efficacy of ritlecitinib 50 mg and baricitinib 4 mg in alopecia areata, but further research needed to establish superiority
Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
research Emerging role of baricitinib in dermatology practice: All we need to know!
Baricitinib effectively treats certain skin conditions but may have serious side effects.
research Eyebrow regrowth in patients with frontal fibrosing alopecia treated with intralesional triamcinolone acetonide
Intralesional triamcinolone acetonide helps regrow eyebrows in patients with frontal fibrosing alopecia.
research JAK inhibition in the treatment of alopecia areata – a promising new dawn?
JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
research Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
Adalimumab significantly improved Hidradenitis Suppurativa and quality of life in two patients.
research Türk kadınlarında görülen saç ve saçlı deri hastalıklarının değerlendirilmesi
Hair and scalp diseases affect 11% of Turkish women, with seborrheic dermatitis being the most common.
research MK-386, an Inhibitor of 5α-Reductase Type 1, Reduces Dihydrotestosterone Concentrations in Serum and Sebum without Affecting Dihydrotestosterone Concentrations in Semen1
MK-386 lowers DHT in blood and skin but not in semen.
research P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
research Excellent response to tofacitinib treatment in a patient with alopecia universalis
A patient with complete hair loss regrew all her hair using tofacitinib.
research Effectiveness and safety of baricitinib in severe alopecia areata: 48‐week results
Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
research Microneedling with Triamcinolone acetonide versus Intralesional Triamcinolone acetonide in treatment of Alopecia Areata
Microneedling with Triamcinolone acetonide is an effective, less invasive, and safe alternative to direct injections for treating alopecia areata.
research Palmoplantar pustulosis–like eruption following tofacitinib therapy for juvenile idiopathic arthritis
Tofacitinib can cause skin eruptions similar to palmoplantar pustulosis.
research Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
Baricitinib is generally safe for long-term use in treating severe alopecia areata.
research Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.